CN102198167B - 用于治疗因细菌病毒引起的流感或高热症状的药物组合物 - Google Patents
用于治疗因细菌病毒引起的流感或高热症状的药物组合物 Download PDFInfo
- Publication number
- CN102198167B CN102198167B CN2011101507753A CN201110150775A CN102198167B CN 102198167 B CN102198167 B CN 102198167B CN 2011101507753 A CN2011101507753 A CN 2011101507753A CN 201110150775 A CN201110150775 A CN 201110150775A CN 102198167 B CN102198167 B CN 102198167B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- diclofenac
- baicalin
- bacterial virus
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010020741 Hyperpyrexia Diseases 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 241000700605 Viruses Species 0.000 title claims abstract description 22
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 21
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 39
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 39
- 229960003321 baicalin Drugs 0.000 claims abstract description 39
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 241001061264 Astragalus Species 0.000 claims abstract description 36
- 235000006533 astragalus Nutrition 0.000 claims abstract description 36
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 36
- 210000004233 talus Anatomy 0.000 claims abstract description 36
- 150000004676 glycans Chemical class 0.000 claims abstract description 34
- 239000005017 polysaccharide Substances 0.000 claims abstract description 34
- 239000007924 injection Substances 0.000 claims abstract description 27
- 238000002347 injection Methods 0.000 claims abstract description 27
- 208000024891 symptom Diseases 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 239000002552 dosage form Substances 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 46
- 229960001259 diclofenac Drugs 0.000 claims description 46
- 206010022000 influenza Diseases 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 230000008901 benefit Effects 0.000 abstract description 4
- 229960001193 diclofenac sodium Drugs 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 238000007796 conventional method Methods 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 231100000397 ulcer Toxicity 0.000 abstract description 2
- 230000027939 micturition Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 35
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 241000287828 Gallus gallus Species 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 12
- 235000010265 sodium sulphite Nutrition 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 235000019698 starch Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000008215 water for injection Substances 0.000 description 12
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 11
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 11
- 206010037660 Pyrexia Diseases 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000003113 dilution method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000019775 Back disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016029 Face oedema Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101507753A CN102198167B (zh) | 2011-06-07 | 2011-06-07 | 用于治疗因细菌病毒引起的流感或高热症状的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101507753A CN102198167B (zh) | 2011-06-07 | 2011-06-07 | 用于治疗因细菌病毒引起的流感或高热症状的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102198167A CN102198167A (zh) | 2011-09-28 |
CN102198167B true CN102198167B (zh) | 2012-07-11 |
Family
ID=44659323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011101507753A Expired - Fee Related CN102198167B (zh) | 2011-06-07 | 2011-06-07 | 用于治疗因细菌病毒引起的流感或高热症状的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102198167B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104161751B (zh) * | 2014-08-16 | 2015-07-08 | 广州一品红制药有限公司 | 一种含炎琥宁的组合物及其应用 |
CN108785681B (zh) * | 2018-09-05 | 2021-04-30 | 四川吉星动物药业有限公司 | 一种兽用的复方解热镇痛抗炎药组合物制剂及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1273115A (zh) * | 1999-05-05 | 2000-11-15 | 方同华 | 一种精制双黄连注射液的生产工艺 |
CN1374083A (zh) * | 2002-04-08 | 2002-10-16 | 广东贝氏日用保健品有限公司 | 抗感冒的复方药物组合物 |
CN1969937A (zh) * | 2005-11-22 | 2007-05-30 | 黄振华 | 一种治疗肝炎的药物组合物 |
CN102068513A (zh) * | 2009-11-20 | 2011-05-25 | 上海中医药大学 | 黄连黄芪黄芩组合物在制备防治糖尿病并发症药物中的应用 |
-
2011
- 2011-06-07 CN CN2011101507753A patent/CN102198167B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1273115A (zh) * | 1999-05-05 | 2000-11-15 | 方同华 | 一种精制双黄连注射液的生产工艺 |
CN1374083A (zh) * | 2002-04-08 | 2002-10-16 | 广东贝氏日用保健品有限公司 | 抗感冒的复方药物组合物 |
CN1969937A (zh) * | 2005-11-22 | 2007-05-30 | 黄振华 | 一种治疗肝炎的药物组合物 |
CN102068513A (zh) * | 2009-11-20 | 2011-05-25 | 上海中医药大学 | 黄连黄芪黄芩组合物在制备防治糖尿病并发症药物中的应用 |
Non-Patent Citations (2)
Title |
---|
张万福.如何进行禽流感的综合防制.《北方牧业》.2009,(第14期),8,10. * |
罗海鹰.中西医结合治疗产后发热临床观察.《中国现代医生》.2009,第47卷(第05期),63-64. * |
Also Published As
Publication number | Publication date |
---|---|
CN102198167A (zh) | 2011-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104257844B (zh) | 一种治疗猪高热病的中药散剂及其制备工艺 | |
CN101953985A (zh) | 一种具有清肺止咳作用的药物 | |
CN102784282A (zh) | 清热解毒退烧药物 | |
CN103721103B (zh) | 用于治疗猪丹毒的药物及其制备方法 | |
CN105709081B (zh) | 治疗鸡传染性鼻炎的药物组合物,其应用及饲料 | |
CN102198167B (zh) | 用于治疗因细菌病毒引起的流感或高热症状的药物组合物 | |
CN101703572A (zh) | 用于畜禽类呼吸道疾病的中药组合物的制备方法及其应用 | |
CN101391065B (zh) | 一种用于治疗急慢性盆腔炎的木鳖子花椒汤 | |
CN102988844A (zh) | 一种妇科凝胶剂及其提取方法 | |
CN102579528B (zh) | 一种防治前列腺疾病的药物组合物 | |
CN103893300B (zh) | 一种治疗奶牛子宫内膜炎的中药组合物及制备方法和应用 | |
CN103948899B (zh) | 一种治疗萎缩性胃炎的藏药 | |
CN103721095B (zh) | 用于预防流行性感冒的中药制剂 | |
CN102793869B (zh) | 一种用于防治猪病毒性疾病的中药组合物及其制备方法 | |
CN105770211A (zh) | 一种医用鼻炎抗菌剂及其制备方法 | |
CN100427118C (zh) | 一种烧烫伤药 | |
CN103585330B (zh) | 一种用于皮肤真菌感染的中药组合物及其制备方法 | |
CN101314026B (zh) | 一种用于家禽的鸭浆膜炎疫苗口服液增效剂及其制备方法 | |
CN108785383A (zh) | 一种抗菌妇科外用药物组合物及其制备方法与应用 | |
CN104622934A (zh) | 橄榄树叶粗提物制备咽喉炎治疗药物的新用途 | |
CN104083731B (zh) | 一种防治家兔混合感染的药物及其制备方法 | |
CN106421220A (zh) | 一种海洋生物护伤喷膜剂的制备方法 | |
CN111956777A (zh) | 一种快速退热的中药及其制备方法 | |
CN102961722B (zh) | 一种治疗老年性便秘的中药组合物 | |
CN105832714B (zh) | 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110928 Assignee: SICHUAN WEIERKANG ANIMAL PHARMACY GROUP Assignor: CHONGQING BASHIDI ANIMAL PHARMACEUTICAL Co.,Ltd. Contract record no.: 2014510000033 Denomination of invention: Pharmaceutical composition for treating flu or hyperpyrexia caused by bacterial virus Granted publication date: 20120711 License type: Exclusive License Record date: 20140429 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190822 Address after: 629000 New Century Industrial Park of Suining Economic and Technological Development Zone, Sichuan Province Patentee after: SICHUAN FEIYANG ANIMAL PHARMACEUTICAL CO.,LTD. Address before: 400700, Room 201, building 2, Beibei incubator center, Chongqing hi tech innovation center, No. 79, natural road, Chongqing, Beibei Patentee before: CHONGQING BASHIDI ANIMAL PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120711 |